logo
Plus   Neg
Share
Email

AstraZeneca: Four-week Dosing Option Approved For Imfinzi In The EU

AstraZeneca PLC (AZN.L,AZN) said the company's Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer. The new option extends dosing from two to four weeks.

The approval was based on data from several Imfinzi clinical trials. The company noted that the approval follows an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, which recommended approval in December 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer has uncovered the counterfeit versions of its Covid-19 vaccine in Mexico and Poland, according to a Wall Street Journal report. The vaccine was developed in partnership with Germany's BioNTech SE. Though there have been several reports of counterfeit versions of the Covid-19 vaccine, this seems to be the first confirmed instance. American Airlines is planning to resume hiring pilots this year to meet a rebound in travel demand in the summer season, reports said citing a company memo. The airline is expected to add 300 pilots by the end of the year and double that in 2022. Verizon Communications Inc. (VZ) reported a profit for the first-quarter that increased 25.4 percent from last year, reflecting growth in wireless service revenue, wireless equipment revenue and total Fios Internet net additions. Quarterly operating revenues rose 4.0 percent from the prior year.
Follow RTT